Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
Coherus is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Our colleagues are experts in analytical and process sciences, deeply experienced in clinical development and regulatory affairs, and have proven commercial and marketing capabilities. Everyone at Coherus is committed to meeting the highest standards, inspiring our teammates, and achieving our goals.
Coherus was founded a decade ago to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.
At Coherus, our employees are our most important asset. We have a dynamic and rewarding organizational culture that offers the opportunity to work with leading industry professionals who are dedicated to making a difference for patients. We are looking for individuals who see unlimited potential in themselves and are motivated by a continuous passion for breaking down barriers and expanding access to lifesaving therapeutics.
Coherus offers a competitive total rewards program comprised of various elements, including competitive base pay, short- and long-term incentives in the form of performance-based cash and equity, as well as health and wellness benefits that include
• Healthcare: Coherus pays 90% of premiums for medical, dental, and vision coverage for our
employees, their eligible spouses, dependents, and domestic partners.
• Health Savings and Flexible Spending Accounts
• Group Life, Disability, and Group Accident Insurance
• 401(k) with company match, and an Employee Stock Purchase Plan (ESPP)
• Paid Time Off (PTO)
• Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
In addition to providing attractive rewards packages, we encourage and support our employees to find the right balance of work and personal time. Coherus offers a variety of activities, perks, and holidays that encourage employees to have a healthy outlook, spend time outside of work with friends and family, and foster a productive and collaborative work environment. Our culture is one in which we challenge and support all our team members to do their best work.
For more information about Coherus, please check out: https://www.coherus.com/about-coherus/
271 articles about Coherus BioSciences
-
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
7/3/2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States.
-
Coherus BioSciences Announces New Employment Inducement Grants - June 27, 2023
6/27/2023
Coherus BioSciences, Inc., announced that effective June 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 48,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $3.84, the closing trading price on the grant date.
-
Here are the top biotech companies in California hiring now on BioSpace’s life sciences–focused job board.
-
The stock deal aims to strengthen Coherus Biosciences’ position in the field of cancer therapeutics and expand its product portfolio.
-
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
6/5/2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the final overall survival (OS) results of the JUPITER-02 study presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting.
-
The company's Humira biosimilar Yusimry will launch in July with a $995 list price. Mark Cuban’s online pharmacy will sell it at a list price of $569.27 plus fees.
-
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023List price of $995 per carton for two 40 mg/0.8 mL autoinjectors
6/1/2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors), the lowest price announced to date of any adalimumab offering in the United States.
-
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
5/22/2023
Coherus BioSciences, Inc. today announced that the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv) is now available for commercial sale in the United States.
-
Coherus Prices Public Offering of Common Stock - May 16, 2023
5/16/2023
Coherus BioSciences, Inc. announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share.
-
Coherus Announces Proposed Public Offering of Common Stock - May 15, 2023
5/15/2023
Coherus BioSciences, Inc., announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock.
-
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
5/8/2023
Coherus BioSciences, Inc. (“Coherus”, “the Company”, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2023 and recent business highlights.
-
Coherus BioSciences to Present at Upcoming Investor Conferences in May 2023
5/4/2023
Coherus BioSciences, Inc. announced that senior management will participate in the following investor conferences.
-
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
5/1/2023
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023.
-
FDA Approves UDENYCA® Autoinjector
3/6/2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the U.S. Food and Drug Administration (“FDA”) approved a single-dose, prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv), a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
-
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
3/6/2023
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2022 and recent business highlights.
-
Coherus BioSciences to Present at Upcoming Investor Conferences in March
3/1/2023
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March.
-
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
2/28/2023
Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023.
-
Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
2/15/2023
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study JUPITER-02 (NCT03581786), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (“NPC”).
-
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
2/15/2023
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study JUPITER-02 (NCT03581786).
-
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
2/13/2023
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published a new code pursuant to the Company’s application for Healthcare Common Procedure Coding System (HCPCS) Q-codes.